Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Microbiota, cirrhosis, and the emerging oral-gut-liver axis
Chathur Acharya, … , Sinem Esra Sahingur, Jasmohan S. Bajaj
Chathur Acharya, … , Sinem Esra Sahingur, Jasmohan S. Bajaj
Published October 5, 2017
Citation Information: JCI Insight. 2017;2(19):e94416. https://doi.org/10.1172/jci.insight.94416.
View: Text | PDF
Review

Microbiota, cirrhosis, and the emerging oral-gut-liver axis

  • Text
  • PDF
Abstract

Cirrhosis is a prevalent cause of morbidity and mortality, especially for those at an advanced decompensated stage. Cirrhosis development and progression involves several important interorgan communications, and recently, the gut microbiome has been implicated in pathophysiology of the disease. Dysbiosis, defined as a pathological change in the microbiome, has a variable effect on the compensated versus decompensated stage of cirrhosis. Adverse microbial changes, both in composition and function, can act at several levels within the gut (stool and mucosal) and have also been described in the blood and oral cavity. While dysbiosis in the oral cavity could be a source of systemic inflammation, current cirrhosis treatment modalities are targeted toward the gut-liver axis and do not address the oral microbiome. As interventions designed to modulate oral dysbiosis may delay progression of cirrhosis, a better understanding of this process is of the utmost importance. The concept of oral microbiota dysbiosis in cirrhosis is relatively new; therefore, this review will highlight the emerging role of the oral-gut-liver axis and introduce perspectives for future research.

Authors

Chathur Acharya, Sinem Esra Sahingur, Jasmohan S. Bajaj

×

Figure 1

Proposed relationship between the gut, liver, and the oral cavity.

Options: View larger image (or click on image) Download as PowerPoint
Proposed relationship between the gut, liver, and the oral cavity.
Infla...
Inflammation in the oral cavity, liver, and the gut can lead to systemic inflammation, thereby inducing endotoxemia as the result of an increase in the relative abundance of potentially pathogenic microbiota in the gut and oral cavity, along with impaired mucosal and systemic immune response and a dampened ability of the liver to handle these insults. Alterations in bile acid profile, gastric acid suppression and potential neuro-hormonal changes that are inherent in cirrhosis also conspire to generate this systemic proinflammatory milieu. SIBO, small intestinal bacterial overgrowth. Illustrated by Rachel Davidowitz.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts